恩替卡韦的合成及其质量评价
[Abstract]:Enticavir was developed by Bristol-Myers Squibb in the 1990s. It was originally designed to treat herpes simplex virus (HSV) infection by using enecavir as a nucleosides analogues of 2-pentacyclodeoxyguanine, which was developed in the 1990s by Bumai-Pishibao (Bumai-Pishibao) Company of the United States. The original purpose of Entekawi is to treat herpes simplex virus infection. It was later found that it had strong anti-HBV ability and relatively low toxicity, so it was listed as a drug for the treatment of chronic hepatitis B. The purpose of this paper is to improve the existing Entekawi synthesis methods, to study the synthesis process, to find new synthesis conditions suitable for industrial production, and to obtain low cost and high stability entecavir raw materials. It creates favorable conditions for the next step of the study of entecavir preparation and produces cheaper and more effective drugs for the treatment of chronic hepatitis B. First of all, the existing synthetic ways of entecavir are reviewed. on the basis of the existing literature reports, for the purpose of industrial production, the products which are easy to obtain are environmentally friendly and low toxic to human body are selected as the starting materials. The development conditions are mild and easy to industrial production and synthesis route, with 伪-piperene, borane dimethyl sulfide complex and cyclopentadiene sodium as starting materials. (1s-trans)-2-[(p-methylbenzoxyl) methyl]-3-cyclopentene-1-ol was obtained by condensation reaction. (1S-trans)-2-[(p-methylbenzoxyl) methyl]-3, 5-cyclopentadiene-1-alcohol is cyclooxidized to (1S-trans)-2-[(p-methyl)-2-[(p-methyl)-2-alcohol under the action of vanadium acetylacetone oxide and tert-butylhydrogen peroxide Benzoxyl) methyl]-oxabicyclo [3.1.0]-cyclopentane-1-alcohol. After the hydroxyl group was protected by methyl benzylgroup, it was coupled with 6-benzyloxyguanine, and then reacted with 6-benzyloxyguanine to give entecavir by oxidation, methylene and deprotection. The obtained products were characterized by elemental analysis, ultraviolet spectroscopy, infrared spectroscopy, nuclear magnetic resonance spectroscopy, mass spectrometry, differential thermal analysis and thermogravimetric analysis. Secondly, the quality standard of this product is established by referring to the standard of import registration (JX20050113) and the requirements of Chinese Pharmacopoeia. HPLC retention time and infrared absorption spectroscopy were used to identify the samples, the properties, specific curl and moisture of the samples were determined, and the residual solvents were determined by gas chromatography combined with the production process. The content of the sample was determined by high performance liquid chromatography (HPLC) and the related substances were examined. Finally, according to the Technical requirements of Physicochemical and quality Standard Research of New drugs (Chemicals) and Appendix XIX X C of Chinese Pharmacopoeia, "guiding principles of Drug Stability Test, preparation Stability Test", the light of this product is carried out. The influencing factors test of high temperature and high humidity and the long-term accelerated stability test show that the product has the same stability as the original Entekawi.
【学位授予单位】:浙江大学
【学位级别】:硕士
【学位授予年份】:2016
【分类号】:R914.5
【相似文献】
相关期刊论文 前10条
1 郭玉香;;恩替卡韦治疗慢性重型乙型病毒性肝炎临床观察[J];中国慢性病预防与控制;2008年03期
2 赵蕊;;慢性重型乙型肝炎患者恩替卡韦治疗效果分析[J];中国公共卫生;2009年06期
3 杨晓欣;宋军红;;恩替卡韦治疗慢性乙型重型肝炎短期疗效观察[J];内蒙古医学杂志;2009年06期
4 韦照永;潘丽莹;覃益;;恩替卡韦联合复方丹参滴丸对慢性乙型肝炎肝纤维化指标的影响[J];现代中西医结合杂志;2009年25期
5 范英丽;袁勇;冯志成;;恩替卡韦联合复方丹参滴丸治疗慢性乙型肝炎肝纤维化的临床研究[J];海南医学院学报;2009年09期
6 刘政芳;潘晨;高海兵;;恩替卡韦联合血浆置换治疗慢性乙型重型肝炎临床观察[J];实用肝脏病杂志;2009年05期
7 陈建红;李群;;恩替卡韦治疗慢性乙型重型肝炎40例分析[J];潍坊医学院学报;2009年03期
8 赵晶;孙海英;;恩替卡韦治疗慢性乙型重型肝炎49例疗效观察[J];中国民康医学;2010年24期
9 夏德全;赵利;曹显刚;;恩替卡韦联合强的松治疗乙型肝炎病毒相关性肾炎19例[J];中外医疗;2010年35期
10 李生英;;恩替卡韦停药不当致肝衰竭1例[J];人民军医;2012年03期
相关会议论文 前10条
1 钟渊斌;;恩替卡韦治疗慢性乙型重型肝炎近期疗效的观察[A];病毒性肝炎慢性化、重症化基础与临床研究进展学术会议论文汇编[C];2009年
2 王鲁文;严少南;向龙奎;龚作炯;;恩替卡韦治疗慢性重型乙型肝炎的疗效观察[A];全国第2届中西医结合传染病学术会议暨国家中医药管理局第1届传染病协作组会议论文汇编[C];2008年
3 纪冬;陈国凤;李永纲;邵清;韩萍;;恩替卡韦治疗慢性乙肝病毒感染患者21例疗效观察及文献回顾[A];中华医学会全国第九次感染病学学术会议论文汇编[C];2006年
4 张建;白鹄;朱玉成;谢士达;;恩替卡韦联合血浆置换治疗慢性乙型重型肝炎22例[A];第一届全国疑难重型肝病大会、第四届全国人工肝及血液净化学术年会论文集[C];2008年
5 林秉滔;庄海珍;陈进;;恩替卡韦治疗慢性乙型重症肝炎疗效观察[A];第十次浙江省中西医结合肝病学术会议论文汇编[C];2008年
6 杨联勇;;恩替卡韦治疗慢性乙型肝炎感染的综述[A];2006年慢性乙型肝炎治疗进展研讨会资料汇编[C];2006年
7 林秉滔;庄海珍;陈进;;恩替卡韦治疗慢性乙型重症肝炎疗效观察[A];2008年浙江省感染病、肝病学术年会论文汇编[C];2008年
8 胡涛;吕志平;;杞菊地黄丸联合恩替卡韦治疗肝肾阴虚型慢性乙型肝炎的临床研究[A];六味地黄类中成药与方剂——临床应用研究论文集[C];2012年
9 杨澍;王洪;徐强胜;王雪刚;曹丽红;洪婉媚;;恩替卡韦对慢性乙型重型肝炎抢救意义分析[A];第6届全国疑难及重症肝病大会论文集[C];2011年
10 杨静;朱萱;王河;;恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效观察[A];第二十五届全国中西医结合消化系统疾病学术会议论文集[C];2013年
相关重要报纸文章 前10条
1 本报记者 陈国东;国产恩替卡韦打造市场新格局[N];医药经济报;2009年
2 国家上海新药安全评价研究中心主任 邓中平;恩替卡韦治疗乙型肝炎的安全性研究[N];中国劳动保障报;2005年
3 侯金林;恩替卡韦:慢性乙型肝炎治疗的新选择[N];中国劳动保障报;2005年
4 陆志城;恩替卡韦:有望成为治疗慢性乙肝的一线药物[N];医药经济报;2006年
5 驻京记者 王丹;恩替卡韦实际临床数据公布[N];医药经济报;2010年
6 记者 靖九江;恩替卡韦可降低肝癌发生率[N];中国医药报;2012年
7 谭德明;乙肝治疗又添新将——恩替卡韦[N];大众卫生报;2003年
8 记者 张旭;长期接受恩替卡韦治疗患者没有产生耐药[N];中国医药报;2006年
9 晓剑;恩替卡韦用于慢性乙型肝炎的治疗[N];中国劳动保障报;2005年
10 国家发改委医药工业信息中心站 郭文;恩替卡韦溢价之路潜藏市场危机[N];医药经济报;2005年
,本文编号:2479793
本文链接:https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2479793.html